Health Care · Services-Health Services

SRTA Strata Critical Medical, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1779128109 filings
Russell 2000

SRTA at a glance

Strata Critical Medical, Inc. (SRTA, SEC CIK 1779128) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Strata Critical Medical, Inc. (SRTA) reported revenue of $197.1 million (down 20.7% from FY2024) and net income of $41.3 million. Diluted EPS was $0.50.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Strata Critical Medical, Inc. (SRTA) shares worth $118.4 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by LAUCK ANDREW on November 5, 2026 of 2,000 shares at $5.00 per share.
  • In the last 90 days, SRTA insiders reported 1 open-market purchase ($10K) and 0 open-market sales ($0) on Form 4, a net purchase of $10K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$197.1M
−20.7% vs prior year
Insiders · 90 days
1 buy · 0 sells
Net +$10K
13F holders
26 funds
$118.4M · +2 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risks disclosed in the December 31, 2025 Form 10-K
  • Carried-forward business risks could materially affect operations and financial condition
  • Common-stock trading price risk from adverse business developments
  • Forward-looking statement risk from actual results differing materially from expectations

Management Discussion & Analysis

  • Revenue $74.1M, up 50.3% YoY from $49.3M, driven by Clinical revenue of $29.2M
  • Total gross margin 22.7% vs 21.6% YoY, with Clinical margin 25.6% and Logistics margin 20.8%
  • Best segment Clinical: $29.2M revenue and $7.5M gross profit, worst Logistics: $44.9M revenue, down 3.5% YoY
  • Cash and equivalents $35.1M vs $31.0M, operating cash flow $19.0M vs $(40.6)M YoY
  • $35.8M acquisition spending and $8.1M property investments, with $15.3M proceeds from Buyer Shares sales
  • Outlook: $41.6M liquidity expected sufficient for current needs through 12 months, with donor supply flattening and clinician costs a headwind

AI summary of the SRTA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced for quarter ended September 30, 2026
  • Press release Exhibit 99.1 contains the financial results and investor-relevant performance details

Item EX-99.1: Item EX-99.1

  • Q3 revenue $74.1M, up 50.3% year over year, driven by acquisitions and clinical revenue growth
  • Clinical revenue $29.2M, up 20.3% sequentially, while Logistics revenue declined 3.5% to $44.9M
Filed Aug 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 financial results for the quarter ended June 30, 2026 announced on August 4, 2026
  • Detailed results and management commentary available in Exhibit 99.1, the accompanying press release

Item EX-99.1: Item EX-99.1

  • Q2 revenue $72.5M, up 60.7% YoY, with Clinical revenue $24.3M and organic Clinical growth 15.1% sequentially
  • Adjusted EBITDA $7.9M, margin 10.9%, up from $2.5M and 5.5% YoY, signaling improved operating leverage
Filed Jun 3, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Stockholders elected William A. Heyburn and Andrew Lauck as Class II directors through the 2029 annual meeting
  • Heyburn received 46,050,902 votes for, while Lauck received 39,525,159, indicating materially stronger support for Heyburn

AI summaries of SRTA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SRTA

Don't miss the next SRTA filing

  • Alerts as it files. A push when SRTA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SRTA, by share count.
  • Ask anything. An AI agent that reads every SRTA filing and answers with sources.

SRTA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
LAUCK ANDREWBuyNov 5, 2026$5.00
Wunsch Scott MFOct 28, 2026$4.76
Wunsch Scott MAOct 28, 2026-
Wunsch Scott MAOct 28, 2026-
Wunsch Scott MAOct 28, 2026-
Heyburn William A.FSep 24, 2026$5.27
Tomkiel Melissa M.FSep 24, 2026$5.27
Heyburn William A.ASep 24, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$248.7M$197.1M
Gross Profit-$29.6M$41.1M
Operating Income--$33.9M-$22.4M
Net Income--$27.3M$41.3M
Gross Margin-11.9%20.9%
Op. Margin--13.6%-11.3%
Net Margin--11.0%21.0%
Balance Sheet
Total Assets-$256.7M$325.5M
Equity-$221.9M$279.1M
ROE--12.3%14.8%
Per Share
EPS$-0.76$-0.35$0.50
Cash Flow
Operating CF--$2.5M-$48.9M
CapEx$2.1M$30.9M$9.6M

Source: XBRL data in Strata Critical Medical, Inc. (SRTA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SRTA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SRTA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$118.4M
Q2 202624$126.1M
Q1 202626$116.3M
Q4 202524$133.8M
Q3 202525$137.1M
Q2 202523$93.3M
Q1 202520$51.3M
Q4 202417$72.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 185 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SRTA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 9, 2026--
10-QNov 3, 2026Analysis
8-KNov 3, 2026Analysis-
4Oct 30, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
4Sep 10, 2026--
4Sep 10, 2026--
4Sep 10, 2026--
4Sep 10, 2026--
4Sep 10, 2026--
4Aug 13, 2026--
10-QAug 4, 2026Analysis
8-KAug 4, 2026Analysis-
4Aug 3, 2026--
4Aug 3, 2026--
4Aug 3, 2026--
4Aug 3, 2026--
4Aug 3, 2026--
4Aug 3, 2026--
4Aug 3, 2026--
4Aug 3, 2026--
4Aug 3, 2026--
4Jun 18, 2026--
4Jun 18, 2026--

Related Health Care companies

All Health Care →

SRTA SEC filings: frequently asked questions

Are SRTA insiders buying or selling?

In the last 90 days, Strata Critical Medical, Inc. (SRTA) officers, directors and 10% owners reported 1 open-market purchase worth $9,998 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold SRTA stock?

As of September 30, 2026, the largest Strata Critical Medical, Inc. (SRTA) holders among the 13F filers tracked by SignalX were Third Point LLC ($25.6 million), BlackRock ($24.9 million), Vanguard Capital Management LLC ($14.8 million), State Street Corp ($9.2 million), Dimensional Fund Advisors ($9.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SRTA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Strata Critical Medical, Inc. (SRTA) reported revenue of $197.1 million (down 20.7% from FY2024) and net income of $41.3 million. Diluted EPS was $0.50. The figures come from the XBRL data in the 10-K.

What did SRTA report in its latest 8-K?

Strata Critical Medical, Inc. (SRTA) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results announced for quarter ended September 30, 2026.

What are the latest SRTA SEC filings?

Strata Critical Medical, Inc. (SRTA) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 9, 2026.

What is SRTA's SEC CIK number?

Strata Critical Medical, Inc. (SRTA)'s SEC Central Index Key (CIK) is 1779128. EDGAR lists every SRTA filing under that number.

Ask anything about SRTA

The research agent reads SRTA's filings, financials, insider trades and 13F holders, then answers with sources.